 | | How to Spot One-of-a-Kind Chances in Biotech | | Mable Buchanan, Assistant Managing Editor, The Oxford Club | Rare (Lucrative) FDA Designation for Promising Coronavirus Drug One special FDA classification helped GW Pharmaceuticals climb nearly $100 a share in three years...
Helped Vertex shoot up 557%...
And pushed Alexion up 809%.
See the latest biotech to win this potentially lucrative designation (for its coronavirus treatment). | | | Editor's Note: As Assistant Managing Editor Mable Buchanan writes in today's Stat Sheet, the biotech sector has proven its profitability.
This is especially true as we race to find cures and vaccines for COVID-19.
But some biotech companies stand head and shoulders above the rest when it comes to their potential to score investors "home runs"...
And Chief Income Strategist Marc Lichtenfeld is unmasking his No. 1 biotech in this special presentation.
An expert in the biotech field, Marc has been watching the sector closely - and his top candidate for beating this virus is currently trading at a 40% discount.
The chances to profit here are so great, he's told me that investors can profit 500% even from the worst biotech around.
For details on his most loved - and most hated - biotechs on the market, click here.
- Rachel Gearhart, Associate Franchise Publisher
In the wake of the COVID-19 crisis, there are two faces to the healthcare industry.
On one side, due to a 60% drop in patient volume, half of independent medical practices have had to lay off physicians, according to the Medical Group Management Association.
Justin Wolfers, an economist at the University of Michigan, remarked, "Nearly half of the Q1 decline in GDP can be attributed to healthcare, which is presumably delaying of elective procedures. | | | "It's a strange reality that in the midst of a pandemic, we have a healthcare-led recession."
On the other side, biotech has proven its resilience as a sector.
Take a look at its long-term recovery from the market bottom set in 2009. Biotech exchange-traded funds (ETFs), like the iShares Nasdaq Biotechnology ETF (Nasdaq: IBB) and the VanEck Vectors Biotech ETF (Nasdaq: BBH), soared as the market bounced back.
And Wednesday's jump in the S&P 500 in response to positive news on the drug development front indicates that we might have a healthcare-led recovery as well.
But not so fast, warns Chief Income Strategist and healthcare investing expert Marc Lichtenfeld. | | | Hang On to Your Wallet... Here Come the Socialists!
 A recent Gallup survey found that 43% of Americans now believe that some form of socialism would be GOOD for the country. So if you're over 40 and you've got two nickels to rub together... you are about to become a target. Your savings, your portfolio, your IRA, your 401(k) or pension... they are the bull's-eye.
But here's a ZERO-DOWNSIDE way to PROTECT YOURSELF! | | | "I would argue that biotech is the most important sector in the market and will be for the next five to 10 years and beyond," Marc says.
But as far as a cure sparking an economic recovery, he says, "It typically takes a long time - years - to cure diseases."
Given the delay in a cure, investors need to drown out the one-trick ponies that fill the mainstream news with questionable claims.
Instead, look to biotech companies with the best track records, best pipelines and best fundamentals.
Case in point...
According to biotech analyst Daniel Ward, in the fourth quarter of 2015, an investor who invested in all 30 companies that reported working on an Ebola vaccine would have lost an average of 2.3%.
Meanwhile, an investor who invested in the most successful of these companies would have made 1.25X their money.
"You can hit some big home runs in the biotech sector," according to Marc. "But you need to manage your risk when trading these stocks."
For the best chance at profits, home in on the individual biotechs with the most potential for treating or preventing COVID-19.
To that end, Marc recently shared several companies that he's been keeping an eye on, including Johnson & Johnson (NYSE: JNJ), Roche Holding (OTC: RHHBY) and others.
But he's sharing his top biotech only with a select few of his readers...
Click here for details on the No. 1 biotech Marc believes is leading the "race to the cure."
There's no doubt that this market is unique. But with one-of-a-kind market meltdowns come one-of-a-kind chances to recover.
Good investing,
Mable | | | | | | Joint Pain? Back Pain? What Hurts?
 Before you take another Tylenol or prescription pill... read this.
You can completely erase your joint pain, starting in seven seconds.
This seven-second relief comes from a natural product...
Shipped FREE to your door through this pain-relief program. | | | | - More From Wealthy Retirement - | | | | | | | | | Stock Legend: "This Is the Best Buying Moment in History"
This stock guru bought Apple in 1996, Netflix in 2005 and Amazon in 2005 too.
Now he says we are sitting on the ultimate buying opportunity. Find out the details on the three stocks he is urging people to buy now. | | | | | |
The Oxford Club is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. Members should be aware that although our track record is highly rated by an independent analysis and has been legally reviewed, investment markets have inherent risks and there can be no guarantee of future profits. The stated returns may also include option trades. 
No comments:
Post a Comment